US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
GB8909916D0
(en)
*
|
1989-04-29 |
1989-06-14 |
Delta Biotechnology Ltd |
Polypeptides
|
US5766883A
(en)
*
|
1989-04-29 |
1998-06-16 |
Delta Biotechnology Limited |
Polypeptides
|
ATE92107T1
(de)
*
|
1989-04-29 |
1993-08-15 |
Delta Biotechnology Ltd |
N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
|
GB8927480D0
(en)
*
|
1989-12-05 |
1990-02-07 |
Delta Biotechnology Ltd |
Mutant fungal strain detection and new promoter
|
US5993805A
(en)
*
|
1991-04-10 |
1999-11-30 |
Quadrant Healthcare (Uk) Limited |
Spray-dried microparticles and their use as therapeutic vehicles
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5698517A
(en)
*
|
1994-03-21 |
1997-12-16 |
University Of Hawaii, Office Of Technology Transfer And Economic Development |
Thyroxin-binding HSA fragments
|
US5674842A
(en)
*
|
1994-10-26 |
1997-10-07 |
Health Research, Incorporated |
Growth inhibitory peptide
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US5723125A
(en)
*
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
EP0947581A4
(de)
*
|
1996-08-08 |
2004-07-28 |
Mitsubishi Pharma Corp |
Kulturmedium und seine verwendung.
|
US6274305B1
(en)
|
1996-12-19 |
2001-08-14 |
Tufts University |
Inhibiting proliferation of cancer cells
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
EP1121425B1
(de)
*
|
1998-10-13 |
2005-06-29 |
The University Of Georgia Research Foundation, Inc. |
Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
|
US20030190740A1
(en)
*
|
1998-10-13 |
2003-10-09 |
The University Of Georgia Research Foundation, Inc |
Stabilized bioactive peptides and methods of identification, synthesis, and use
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1276849A4
(de)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
PT2275449T
(pt)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
KR20030068536A
(ko)
*
|
2000-09-11 |
2003-08-21 |
다나-파버 캔서 인스티튜트 |
Muc1 세포외 도메인 및 이로부터 유래된 암 치료조성물과 방법
|
SI1724284T1
(sl)
|
2000-12-07 |
2009-12-31 |
Lilly Co Eli |
Glp-1 fuzijski proteini
|
US20020110841A1
(en)
*
|
2000-12-22 |
2002-08-15 |
KUFE Donald W. |
Regulation of cell growth by MUC1
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
WO2003030821A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CN105131104B
(zh)
|
2001-10-10 |
2018-11-16 |
诺和诺德公司 |
肽的重构和糖缀合
|
NZ532027A
(en)
|
2001-10-10 |
2008-09-26 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
EP1463752A4
(de)
*
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
Albuminfusionsproteine
|
EP2277889B1
(de)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusionsproteine von Albumin und Interferon beta
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
KR20040089608A
(ko)
|
2002-02-07 |
2004-10-21 |
델타 바이오테크놀로지 리미티드 |
Hiv 억제 단백질
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
GB0217033D0
(en)
|
2002-07-23 |
2002-08-28 |
Delta Biotechnology Ltd |
Gene and polypeptide sequences
|
JP2006524036A
(ja)
|
2002-11-08 |
2006-10-26 |
アブリンクス エン.ヴェー. |
腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用
|
CA2513213C
(en)
|
2003-01-22 |
2013-07-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
WO2004092339A2
(en)
*
|
2003-04-11 |
2004-10-28 |
Ilex Products, Inc. |
Modulation of muc1 mediated signal transduction
|
WO2005042573A1
(en)
*
|
2003-10-24 |
2005-05-12 |
Dana-Farber Cancer Institute, Inc. |
Modulation of the interaction of muc1 with muc1 ligands
|
BRPI0507026A
(pt)
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
proteìnas de fusão de albumina
|
US20070202134A1
(en)
*
|
2004-02-23 |
2007-08-30 |
Kufe Donald W |
Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
|
US7973139B2
(en)
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
US20060204512A1
(en)
|
2004-09-23 |
2006-09-14 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
CN101724071A
(zh)
|
2004-10-08 |
2010-06-09 |
杜门蒂斯有限公司 |
抗肿瘤坏死因子受体1的单域抗体及其使用方法
|
KR20140077946A
(ko)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
EP2054437A2
(de)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin-fusionsproteine
|
EP2615108B1
(de)
|
2006-09-08 |
2016-10-26 |
Ambrx, Inc. |
Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
|
US7884184B2
(en)
|
2007-01-30 |
2011-02-08 |
Epivax, Inc. |
Regulatory T cell epitopes, compositions and uses thereof
|
US7871784B2
(en)
*
|
2007-02-02 |
2011-01-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
|
US7972870B2
(en)
|
2007-02-02 |
2011-07-05 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
|
US20100183596A1
(en)
|
2007-04-12 |
2010-07-22 |
Hester Jeanette Bootsma |
Virulence Factors of Streptoccus Pnuemoniae
|
MX2009011109A
(es)
|
2007-04-17 |
2009-12-01 |
Plant Res Int Bv |
Glicosilación tipo mamífera en plantas para la expresión de glicosil-transferasas no mamíferas.
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
KR20100018040A
(ko)
|
2007-06-06 |
2010-02-16 |
도만티스 리미티드 |
프로테아제 내성 폴리펩티드를 선택하는 방법
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
EP2930182A1
(de)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modifizierte insulinpolypeptide und deren verwendungen
|
US10138283B2
(en)
|
2008-07-23 |
2018-11-27 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
EP2174664A1
(de)
|
2008-10-07 |
2010-04-14 |
Stichting Katholieke Universiteit, more particularly the Radboud University Nijmegen Medical Centre |
Neue Virulenzfaktoren von Pneumokokken
|
IT1392551B1
(it)
*
|
2008-11-25 |
2012-03-09 |
Bioindustry Park Del Canavese S P A |
Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
|
AU2009324037B2
(en)
|
2008-12-05 |
2015-07-30 |
Glaxo Group Limited |
Methods for selecting protease resistant polypeptides
|
JP5936112B2
(ja)
|
2009-02-11 |
2016-06-15 |
アルブミディクス アクティーゼルスカブ |
アルブミン変異体及び複合体
|
WO2010094720A2
(en)
|
2009-02-19 |
2010-08-26 |
Glaxo Group Limited |
Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
|
JP5766179B2
(ja)
|
2009-04-27 |
2015-08-19 |
ノバルティス アーゲー |
筋肉増殖を増加させるための組成物および方法
|
MX2011011338A
(es)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
|
JP2012532619A
(ja)
|
2009-07-16 |
2012-12-20 |
グラクソ グループ リミテッド |
Tnfr1を部分的に阻害するためのアンタゴニスト、用途および方法
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
ES2552177T3
(es)
|
2009-10-27 |
2015-11-26 |
Glaxo Group Limited |
Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
CN105567699A
(zh)
|
2009-10-30 |
2016-05-11 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
GB0919837D0
(en)
|
2009-11-13 |
2009-12-30 |
Isis Innovation |
Method of treatment and screening method
|
BR112012015597A2
(pt)
|
2009-12-21 |
2017-01-31 |
Ambrx Inc |
peptídeos de somatotropina suínos modificados e seus usos
|
MX349301B
(es)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Polipéptidos de somatotropina bovina modificados y sus usos.
|
WO2011105891A1
(en)
|
2010-02-23 |
2011-09-01 |
Stichting Katholieke Universiteit, More Particularly The Radboud University Nijmegen Medical Centre |
Combination vaccine for streptococcus
|
CN106977608A
(zh)
|
2010-04-09 |
2017-07-25 |
阿尔布麦狄克斯公司 |
白蛋白衍生物和变体
|
HUE045845T2
(hu)
|
2010-08-17 |
2021-12-28 |
Ambrx Inc |
Módosított relaxin polipeptidek és felhasználásuk
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
AU2011336470B8
(en)
|
2010-12-01 |
2017-09-14 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
DK2707391T3
(en)
|
2011-05-13 |
2018-02-05 |
Gamamabs Pharma |
ANTIBODIES AGAINST HER3
|
CN108373502B
(zh)
|
2011-05-20 |
2022-03-22 |
H.伦德贝克公司 |
抗cgrp组合物及其用途
|
CN103957935B
(zh)
|
2011-05-20 |
2018-04-03 |
奥尔德生物控股有限责任公司 |
抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
|
KR102098546B1
(ko)
|
2011-05-20 |
2020-04-07 |
앨더바이오 홀딩스 엘엘씨 |
필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
|
CN103747803B
(zh)
|
2011-06-22 |
2016-10-12 |
国家医疗保健研究所 |
抗axl抗体及其用途
|
EP2723376B1
(de)
|
2011-06-22 |
2018-12-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl-antikörper und verwendungen damit
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
ES2692519T3
(es)
|
2011-07-01 |
2018-12-04 |
Novartis Ag |
Método para tratar trastornos metabólicos
|
US20140148390A1
(en)
|
2011-07-08 |
2014-05-29 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
US20140187744A1
(en)
*
|
2011-08-10 |
2014-07-03 |
Nipro Corporation |
Bilirubin Excretion Enhancer
|
WO2013075066A2
(en)
|
2011-11-18 |
2013-05-23 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
BR112014018679A2
(pt)
|
2012-03-16 |
2017-07-04 |
Novozymes Biopharma Dk As |
variantes de albumina
|
WO2013170636A1
(zh)
|
2012-05-18 |
2013-11-21 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
MX2015005363A
(es)
|
2012-11-08 |
2015-11-06 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
SI2953969T1
(sl)
|
2013-02-08 |
2020-01-31 |
Novartis Ag |
Protitelesa proti-IL-17A in njihova uporaba v zdravljenju avtoimunskih in vnetnih motenj
|
WO2014165093A2
(en)
|
2013-03-13 |
2014-10-09 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
MX2016000220A
(es)
|
2013-07-03 |
2016-08-18 |
Alder Biopharmaceuticals Inc |
Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
|
CN105960414A
(zh)
|
2013-08-14 |
2016-09-21 |
诺华股份有限公司 |
治疗散发性包涵体肌炎的方法
|
CN105849125B
(zh)
|
2013-11-07 |
2020-05-15 |
国家医疗保健研究所 |
神经调节蛋白变构抗her3抗体
|
CN112043835B
(zh)
|
2013-12-06 |
2022-10-21 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
US11376333B2
(en)
*
|
2013-12-23 |
2022-07-05 |
Covalab |
mTG substrates for covalent conjugation of compounds
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
US20170204149A1
(en)
|
2014-06-23 |
2017-07-20 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof
|
EP3161001A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
|
EP3786182A1
(de)
|
2014-11-19 |
2021-03-03 |
Axon Neuroscience SE |
Humanisierte tau-antikörper bei alzheimer-krankheit
|
ES2764299T3
(es)
|
2014-12-09 |
2020-06-02 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales humanos contra AXL
|
EP3835319A1
(de)
|
2014-12-19 |
2021-06-16 |
Alder Biopharmaceuticals, Inc. |
Humanisierte anti-acth-antikörper und verwendungen davon
|
NL2014148B1
(en)
|
2015-01-16 |
2017-01-05 |
Univ Erasmus Med Ct Rotterdam |
Combination vaccine for camelids.
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
JP6995627B2
(ja)
|
2015-05-19 |
2022-02-04 |
イエール ユニバーシティ |
病的石灰化状態を治療するための組成物およびそれを使用する方法
|
WO2016188911A1
(en)
|
2015-05-22 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
|
WO2017023863A1
(en)
|
2015-07-31 |
2017-02-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
WO2017029407A1
(en)
|
2015-08-20 |
2017-02-23 |
Albumedix A/S |
Albumin variants and conjugates
|
WO2017066719A2
(en)
|
2015-10-14 |
2017-04-20 |
Research Institute At Nationwide Children's Hospital |
Hu specific interfering agents
|
LT3368571T
(lt)
|
2015-10-30 |
2023-02-10 |
The Regents Of The University Of California |
Į transformuojantį augimo faktorių beta atsaką sukuriantys polipeptidai ir jų panaudojimo būdai
|
US20190000923A1
(en)
|
2015-12-22 |
2019-01-03 |
Novartis Ag |
Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
KR102640157B1
(ko)
|
2016-03-22 |
2024-02-27 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
인간화 항-클라우딘-1 항체 및 이의 용도
|
US10202435B2
(en)
|
2016-04-15 |
2019-02-12 |
Alder Biopharmaceuticals, Inc. |
Anti-PACAP antibodies and uses thereof
|
BR112019001693A2
(pt)
|
2016-07-29 |
2019-07-02 |
Ct Hospitalier Universitaire Toulouse |
anticorpos direcionados a macrófagos associados a tumores e seus usos
|
CA3049114A1
(en)
|
2017-01-04 |
2018-07-12 |
Lauren O. Bakaletz |
Antibody fragments for the treatment of biofilm-related disorders
|
CA3049105A1
(en)
|
2017-01-04 |
2018-07-12 |
Lauren O. Bakaletz |
Dnabii vaccines and antibodies with enhanced activity
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
CA3056088A1
(en)
|
2017-03-15 |
2018-09-20 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
AU2018240117A1
(en)
|
2017-03-24 |
2019-09-19 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for preventing and treating heart disease
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
CN110785433A
(zh)
|
2017-06-28 |
2020-02-11 |
诺华股份有限公司 |
预防和治疗尿失禁的方法
|
WO2019102435A1
(en)
|
2017-11-27 |
2019-05-31 |
Euro-Celtique S.A. |
Humanized antibodies targeting human tissue factor
|
EP3552631A1
(de)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
JP2022512580A
(ja)
|
2018-10-05 |
2022-02-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
細菌バイオフィルムの酵素的破壊のための組成物および方法
|
EP3914282A1
(de)
|
2019-01-25 |
2021-12-01 |
Ospedale San Raffaele S.r.l. |
Inhibitor von dux4 und verwendungen davon
|
US20220177558A1
(en)
|
2019-03-25 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
BR112021024938A2
(pt)
|
2019-06-12 |
2022-01-25 |
Novartis Ag |
Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
|
AU2020311897A1
(en)
|
2019-07-08 |
2022-02-03 |
Research Institute At Nationwide Children's Hospital |
Antibody compositions for disrupting biofilms
|
US20220324962A1
(en)
|
2019-09-27 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
US20210147525A1
(en)
|
2019-10-18 |
2021-05-20 |
The Regents Of The University Of California |
Methods and compositions for treating pathogenic blood vessel disorders
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
BR112022013468A2
(pt)
|
2020-01-10 |
2022-09-13 |
Inst Nat Sante Rech Med |
Proteínas rspo1 e seu uso
|
AU2020202454A1
(en)
|
2020-04-06 |
2021-10-21 |
H. Lundbeck A/S |
Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
EP4153636A1
(de)
|
2020-06-29 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Einzeldomänenantikörper gegen protein s und polypeptide damit
|
US11739166B2
(en)
|
2020-07-02 |
2023-08-29 |
Davol Inc. |
Reactive polysaccharide-based hemostatic agent
|
WO2022130182A1
(en)
|
2020-12-14 |
2022-06-23 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
JP2023535884A
(ja)
|
2021-06-22 |
2023-08-22 |
ノバルティス アーゲー |
化膿性汗腺炎の処置における使用のための二特異性抗体
|
IL310154A
(en)
|
2021-07-15 |
2024-03-01 |
Diogenx |
Recombinant variants of R-SPONDIN proteins
|
WO2023026245A1
(en)
|
2021-08-27 |
2023-03-02 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
WO2023170247A1
(en)
|
2022-03-11 |
2023-09-14 |
Mablink Bioscience |
Antibody-drug conjugates and their uses
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|